APO Research
Talk to an analyst

APO RESEARCH · REPORT

Retinal Degenerative Disease Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Retinal Degenerative Disease Treatment Drugs Industry Research Report 2026

25 December 2025121 pages

Choose your research edition.

Industry ResearchRetinal Degenerative Disease Treatment Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Retinal Degenerative Disease Treatment Drugs Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Retinal Degenerative Disease Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Retinal Degenerative Disease Treatment Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Retinal Degenerative Disease Treatment Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Retinal Degenerative Disease Treatment Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Retinal Degenerative Disease Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Retinal Degenerative Disease Treatment Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Retinal Degenerative Disease Treatment Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Retinal Degenerative Disease Treatment Drugs include Coherus BioSciences, Inc, jCyte, Inc., Kodiak Sciences, Merck, Oxurion（ThromboGenics）, Roche, Santen Pharmaceutical, Takeda and Valeant Pharmaceuticals International，Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Retinal Degenerative Disease Treatment Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Retinal Degenerative Disease Treatment Drugs Market by Company

Coherus BioSciences, Inc

jCyte, Inc.

Kodiak Sciences

Merck

Oxurion（ThromboGenics）

Roche

Santen Pharmaceutical

Takeda

Valeant Pharmaceuticals International，Inc

Bayer HealthCare

Novartis

Regeneron Pharmaceuticals

Kanghong Pharma

Retinal Degenerative Disease Treatment Drugs Segment by Type

Retinitis Pigmentosa (RP) Treatment Drug

Age Related Macular Degeneration (AMD) Treatment Drug

Retinal Degenerative Disease Treatment Drugs Segment by Application

Clinic

Hospital

Others

Retinal Degenerative Disease Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Degenerative Disease Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Retinal Degenerative Disease Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Degenerative Disease Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Retinal Degenerative Disease Treatment Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Retinal Degenerative Disease Treatment Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Retinal Degenerative Disease Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Retinal Degenerative Disease Treatment Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Retinal Degenerative Disease Treatment Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Retinal Degenerative Disease Treatment Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Retinal Degenerative Disease Treatment Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Retinal Degenerative Disease Treatment Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Retinal Degenerative Disease Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Retinal Degenerative Disease Treatment Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Retinal Degenerative Disease Treatment Drugs, Product Type & Application Table 14. Global Retinal Degenerative Disease Treatment Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Retinal Degenerative Disease Treatment Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Coherus BioSciences, Inc Company Information Table 19. Coherus BioSciences, Inc Business Overview Table 20. Coherus BioSciences, Inc Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Coherus BioSciences, Inc Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 22. Coherus BioSciences, Inc Recent Developments Table 23. jCyte, Inc. Company Information Table 24. jCyte, Inc. Business Overview Table 25. jCyte, Inc. Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. jCyte, Inc. Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 27. jCyte, Inc. Recent Developments Table 28. Kodiak Sciences Company Information Table 29. Kodiak Sciences Business Overview Table 30. Kodiak Sciences Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Kodiak Sciences Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 32. Kodiak Sciences Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Merck Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 37. Merck Recent Developments Table 38. Oxurion（ThromboGenics） Company Information Table 39. Oxurion（ThromboGenics） Business Overview Table 40. Oxurion（ThromboGenics） Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Oxurion（ThromboGenics） Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 42. Oxurion（ThromboGenics） Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Roche Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 47. Roche Recent Developments Table 48. Santen Pharmaceutical Company Information Table 49. Santen Pharmaceutical Business Overview Table 50. Santen Pharmaceutical Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Santen Pharmaceutical Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 52. Santen Pharmaceutical Recent Developments Table 53. Takeda Company Information Table 54. Takeda Business Overview Table 55. Takeda Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Takeda Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 57. Takeda Recent Developments Table 58. Valeant Pharmaceuticals International，Inc Company Information Table 59. Valeant Pharmaceuticals International，Inc Business Overview Table 60. Valeant Pharmaceuticals International，Inc Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Valeant Pharmaceuticals International，Inc Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 62. Valeant Pharmaceuticals International，Inc Recent Developments Table 63. Bayer HealthCare Company Information Table 64. Bayer HealthCare Business Overview Table 65. Bayer HealthCare Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Bayer HealthCare Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 67. Bayer HealthCare Recent Developments Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novartis Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 72. Novartis Recent Developments Table 73. Regeneron Pharmaceuticals Company Information Table 74. Regeneron Pharmaceuticals Business Overview Table 75. Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 77. Regeneron Pharmaceuticals Recent Developments Table 78. Kanghong Pharma Company Information Table 79. Kanghong Pharma Business Overview Table 80. Kanghong Pharma Retinal Degenerative Disease Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Kanghong Pharma Retinal Degenerative Disease Treatment Drugs Product Portfolio Table 82. Kanghong Pharma Recent Developments Table 83. Global Retinal Degenerative Disease Treatment Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Retinal Degenerative Disease Treatment Drugs Sales by Region (2021-2026) & (K Units) Table 85. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Region (2021-2026) Table 86. Global Retinal Degenerative Disease Treatment Drugs Sales by Region (2027-2032) & (K Units) Table 87. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Region (2027-2032) Table 88. Global Retinal Degenerative Disease Treatment Drugs Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Region (2021-2026) Table 90. Global Retinal Degenerative Disease Treatment Drugs Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Region (2027-2032) Table 92. North America Retinal Degenerative Disease Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 94. North America Retinal Degenerative Disease Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 95. North America Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Retinal Degenerative Disease Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Retinal Degenerative Disease Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 99. Europe Retinal Degenerative Disease Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 100. Europe Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Retinal Degenerative Disease Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Retinal Degenerative Disease Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 104. Asia Pacific Retinal Degenerative Disease Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 105. Asia Pacific Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Retinal Degenerative Disease Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Retinal Degenerative Disease Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 109. South America Retinal Degenerative Disease Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 110. South America Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Retinal Degenerative Disease Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 114. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 115. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Retinal Degenerative Disease Treatment Drugs Sales by Type (2021-2026) & (K Units) Table 118. Global Retinal Degenerative Disease Treatment Drugs Sales by Type (2027-2032) & (K Units) Table 119. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Type (2021-2026) Table 120. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Type (2027-2032) Table 121. Global Retinal Degenerative Disease Treatment Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Retinal Degenerative Disease Treatment Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Type (2021-2026) Table 124. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Type (2027-2032) Table 125. Global Retinal Degenerative Disease Treatment Drugs Price by Type (2021-2026) & (US$/Unit) Table 126. Global Retinal Degenerative Disease Treatment Drugs Price by Type (2027-2032) & (US$/Unit) Table 127. Global Retinal Degenerative Disease Treatment Drugs Sales by Application (2021-2026) & (K Units) Table 128. Global Retinal Degenerative Disease Treatment Drugs Sales by Application (2027-2032) & (K Units) Table 129. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Application (2021-2026) Table 130. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Application (2027-2032) Table 131. Global Retinal Degenerative Disease Treatment Drugs Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Retinal Degenerative Disease Treatment Drugs Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Application (2021-2026) Table 134. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Application (2027-2032) Table 135. Global Retinal Degenerative Disease Treatment Drugs Price by Application (2021-2026) & (US$/Unit) Table 136. Global Retinal Degenerative Disease Treatment Drugs Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Retinal Degenerative Disease Treatment Drugs Distributors List Table 140. Retinal Degenerative Disease Treatment Drugs Customers List Table 141. Retinal Degenerative Disease Treatment Drugs Industry Trends Table 142. Retinal Degenerative Disease Treatment Drugs Industry Drivers Table 143. Retinal Degenerative Disease Treatment Drugs Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Retinal Degenerative Disease Treatment Drugs Product Image Figure 5. Global Retinal Degenerative Disease Treatment Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Retinal Degenerative Disease Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Retinal Degenerative Disease Treatment Drugs Sales (2021-2032) & (K Units) Figure 8. Global Retinal Degenerative Disease Treatment Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Retinitis Pigmentosa (RP) Treatment Drug Product Image Figure 10. Age Related Macular Degeneration (AMD) Treatment Drug Product Image Figure 11. Clinic Product Image Figure 12. Hospital Product Image Figure 13. Others Product Image Figure 14. Global Retinal Degenerative Disease Treatment Drugs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Retinal Degenerative Disease Treatment Drugs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Retinal Degenerative Disease Treatment Drugs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Retinal Degenerative Disease Treatment Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Retinal Degenerative Disease Treatment Drugs Sales by Region in 2025 Figure 20. Global Retinal Degenerative Disease Treatment Drugs Revenue by Region in 2025 Figure 21. North America Retinal Degenerative Disease Treatment Drugs Market Size by Country in 2025 Figure 22. North America Retinal Degenerative Disease Treatment Drugs Sales Market Share by Country (2021-2032) Figure 23. North America Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 24. United States Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Retinal Degenerative Disease Treatment Drugs Market Size by Country in 2025 Figure 28. Europe Retinal Degenerative Disease Treatment Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Retinal Degenerative Disease Treatment Drugs Market Size by Country in 2025 Figure 41. Asia Pacific Retinal Degenerative Disease Treatment Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 43. China Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Retinal Degenerative Disease Treatment Drugs Market Size by Country in 2025 Figure 52. South America Retinal Degenerative Disease Treatment Drugs Sales Market Share by Country (2021-2032) Figure 53. South America Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 54. Brazil Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Country (2021-2032) Figure 60. Egypt Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Retinal Degenerative Disease Treatment Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Type (2021-2032) Figure 66. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Type (2021-2032) Figure 67. Global Retinal Degenerative Disease Treatment Drugs Price (US$/Unit) by Type (2021-2032) Figure 68. Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Application (2021-2032) Figure 69. Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Application (2021-2032) Figure 70. Global Retinal Degenerative Disease Treatment Drugs Price (US$/Unit) by Application (2021-2032) Figure 71. Retinal Degenerative Disease Treatment Drugs Value Chain Figure 72. Retinal Degenerative Disease Treatment Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Retinal Degenerative Disease Treatment Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Retinitis Pigmentosa (RP) Treatment Drug
  • Age Related Macular Degeneration (AMD) Treatment Drug
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Coherus BioSciences, Inc
  • jCyte, Inc.
  • Kodiak Sciences
  • Merck
  • Oxurion（ThromboGenics）
  • Roche
  • Santen Pharmaceutical
  • Takeda
  • Valeant Pharmaceuticals International，Inc
  • Bayer HealthCare
  • Novartis
  • Regeneron Pharmaceuticals
  • Kanghong Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Retinal Degenerative Disease Treatment Drugs Market Size (2021-2032)
  4. 2.2.2 Global Retinal Degenerative Disease Treatment Drugs Sales (2021-2032)
  5. 2.2.3 Global Retinal Degenerative Disease Treatment Drugs Market Average Price (2021-2032)
  6. 2.3 Retinal Degenerative Disease Treatment Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Retinitis Pigmentosa (RP) Treatment Drug
  9. 2.3.3 Age Related Macular Degeneration (AMD) Treatment Drug
  10. 2.4 Retinal Degenerative Disease Treatment Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Clinic
  13. 2.4.3 Hospital
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Retinal Degenerative Disease Treatment Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Retinal Degenerative Disease Treatment Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Retinal Degenerative Disease Treatment Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Retinal Degenerative Disease Treatment Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Retinal Degenerative Disease Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Retinal Degenerative Disease Treatment Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Retinal Degenerative Disease Treatment Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Retinal Degenerative Disease Treatment Drugs, Established Date
  9. 3.9 Global Retinal Degenerative Disease Treatment Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Coherus BioSciences, Inc
  2. 4.1.1 Coherus BioSciences, Inc Company Information
  3. 4.1.2 Coherus BioSciences, Inc Business Overview
  4. 4.1.3 Coherus BioSciences, Inc Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Coherus BioSciences, Inc Retinal Degenerative Disease Treatment Drugs Product Portfolio
  6. 4.1.5 Coherus BioSciences, Inc Recent Developments
  7. 4.2 jCyte, Inc.
  8. 4.2.1 jCyte, Inc. Company Information
  9. 4.2.2 jCyte, Inc. Business Overview
  10. 4.2.3 jCyte, Inc. Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 jCyte, Inc. Retinal Degenerative Disease Treatment Drugs Product Portfolio
  12. 4.2.5 jCyte, Inc. Recent Developments
  13. 4.3 Kodiak Sciences
  14. 4.3.1 Kodiak Sciences Company Information
  15. 4.3.2 Kodiak Sciences Business Overview
  16. 4.3.3 Kodiak Sciences Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Kodiak Sciences Retinal Degenerative Disease Treatment Drugs Product Portfolio
  18. 4.3.5 Kodiak Sciences Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck Retinal Degenerative Disease Treatment Drugs Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 Oxurion（ThromboGenics）
  26. 4.5.1 Oxurion（ThromboGenics） Company Information
  27. 4.5.2 Oxurion（ThromboGenics） Business Overview
  28. 4.5.3 Oxurion（ThromboGenics） Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Oxurion（ThromboGenics） Retinal Degenerative Disease Treatment Drugs Product Portfolio
  30. 4.5.5 Oxurion（ThromboGenics） Recent Developments
  31. 4.6 Roche
  32. 4.6.1 Roche Company Information
  33. 4.6.2 Roche Business Overview
  34. 4.6.3 Roche Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Roche Retinal Degenerative Disease Treatment Drugs Product Portfolio
  36. 4.6.5 Roche Recent Developments
  37. 4.7 Santen Pharmaceutical
  38. 4.7.1 Santen Pharmaceutical Company Information
  39. 4.7.2 Santen Pharmaceutical Business Overview
  40. 4.7.3 Santen Pharmaceutical Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Santen Pharmaceutical Retinal Degenerative Disease Treatment Drugs Product Portfolio
  42. 4.7.5 Santen Pharmaceutical Recent Developments
  43. 4.8 Takeda
  44. 4.8.1 Takeda Company Information
  45. 4.8.2 Takeda Business Overview
  46. 4.8.3 Takeda Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Takeda Retinal Degenerative Disease Treatment Drugs Product Portfolio
  48. 4.8.5 Takeda Recent Developments
  49. 4.9 Valeant Pharmaceuticals International，Inc
  50. 4.9.1 Valeant Pharmaceuticals International，Inc Company Information
  51. 4.9.2 Valeant Pharmaceuticals International，Inc Business Overview
  52. 4.9.3 Valeant Pharmaceuticals International，Inc Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Valeant Pharmaceuticals International，Inc Retinal Degenerative Disease Treatment Drugs Product Portfolio
  54. 4.9.5 Valeant Pharmaceuticals International，Inc Recent Developments
  55. 4.10 Bayer HealthCare
  56. 4.10.1 Bayer HealthCare Company Information
  57. 4.10.2 Bayer HealthCare Business Overview
  58. 4.10.3 Bayer HealthCare Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Bayer HealthCare Retinal Degenerative Disease Treatment Drugs Product Portfolio
  60. 4.10.5 Bayer HealthCare Recent Developments
  61. 4.11 Novartis
  62. 4.11.1 Novartis Company Information
  63. 4.11.2 Novartis Business Overview
  64. 4.11.3 Novartis Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novartis Retinal Degenerative Disease Treatment Drugs Product Portfolio
  66. 4.11.5 Novartis Recent Developments
  67. 4.12 Regeneron Pharmaceuticals
  68. 4.12.1 Regeneron Pharmaceuticals Company Information
  69. 4.12.2 Regeneron Pharmaceuticals Business Overview
  70. 4.12.3 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Drugs Product Portfolio
  72. 4.12.5 Regeneron Pharmaceuticals Recent Developments
  73. 4.13 Kanghong Pharma
  74. 4.13.1 Kanghong Pharma Company Information
  75. 4.13.2 Kanghong Pharma Business Overview
  76. 4.13.3 Kanghong Pharma Retinal Degenerative Disease Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Kanghong Pharma Retinal Degenerative Disease Treatment Drugs Product Portfolio
  78. 4.13.5 Kanghong Pharma Recent Developments
5 Global Retinal Degenerative Disease Treatment Drugs Market Scenario by Region
  1. 5.1 Global Retinal Degenerative Disease Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Retinal Degenerative Disease Treatment Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Retinal Degenerative Disease Treatment Drugs Sales by Region: 2027-2032
  5. 5.3 Global Retinal Degenerative Disease Treatment Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Retinal Degenerative Disease Treatment Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Retinal Degenerative Disease Treatment Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Retinal Degenerative Disease Treatment Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Retinal Degenerative Disease Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Retinal Degenerative Disease Treatment Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Retinal Degenerative Disease Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Retinal Degenerative Disease Treatment Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Retinal Degenerative Disease Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Retinal Degenerative Disease Treatment Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Retinal Degenerative Disease Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Retinal Degenerative Disease Treatment Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Retinal Degenerative Disease Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Retinal Degenerative Disease Treatment Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Retinal Degenerative Disease Treatment Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Retinal Degenerative Disease Treatment Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Retinal Degenerative Disease Treatment Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Retinal Degenerative Disease Treatment Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Retinal Degenerative Disease Treatment Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Retinal Degenerative Disease Treatment Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Retinal Degenerative Disease Treatment Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Retinal Degenerative Disease Treatment Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Retinal Degenerative Disease Treatment Drugs Value Chain Analysis
  2. 8.1.1 Retinal Degenerative Disease Treatment Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Retinal Degenerative Disease Treatment Drugs Production Mode & Process
  5. 8.2 Retinal Degenerative Disease Treatment Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Retinal Degenerative Disease Treatment Drugs Distributors
  8. 8.2.3 Retinal Degenerative Disease Treatment Drugs Customers
9 Global Retinal Degenerative Disease Treatment Drugs Analyzing Market Dynamics
  1. 9.1 Retinal Degenerative Disease Treatment Drugs Industry Trends
  2. 9.2 Retinal Degenerative Disease Treatment Drugs Industry Drivers
  3. 9.3 Retinal Degenerative Disease Treatment Drugs Industry Opportunities and Challenges
  4. 9.4 Retinal Degenerative Disease Treatment Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst